Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Allurion Technologies's operating assets for the quarter that ended in Mar. 2026 was $8.94 Mil. Allurion Technologies's operating liabilities for the quarter that ended in Mar. 2026 was $62.46 Mil. Allurion Technologies's Total Assets for the quarter that ended in Dec. 2025 was $15.77 Mil. Therefore, Allurion Technologies's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -3.39.
Allurion Technologies Scaled Net Operating Assets Related Terms
Allurion Technologies Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Allurion Technologies's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allurion Technologies Scaled Net Operating Assets Chart
ALURD vs ALRTF, VVOS, SINT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Allurion Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -3.39 mean?
Allurion Technologies (ALURD) has a Scaled Net Operating Assets of -3.39 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Allurion Technologies and its competitors.
Is Allurion Technologies' Scaled Net Operating Assets too high?
Allurion Technologies' current Scaled Net Operating Assets is -3.39. Overall, Allurion Technologies has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' Scaled Net Operating Assets compare to ALRTF and VVOS?
Allurion Technologies' Scaled Net Operating Assets of -3.39 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Allurion Technologies and its competitors. Allurion Technologies's current Scaled Net Operating Assets is -3.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.66, compared to a current price of $5.91 — trading 44.6% below its estimated fair value. The current Scaled Net Operating Assets is -3.39. Allurion Technologies' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current Scaled Net Operating Assets is -3.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALURD) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $5.91 is trading 44.6% below its estimated GF Value™ of $10.66.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALURD:
Scaled Net Operating Assets: -3.39
GF Value™: $10.66 vs. price of $5.91 (44.6% below fair value)
No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
16GF Score
Get the complete analysis for ALURD
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALURD has been successfully added to your 
